Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Moderna, Inc. (MRNA) vs Vital Farms Inc (VITL) Price & Performance

Moderna, Inc.Trade
Vital Farms IncTrade

Price performance (Past 24H)

Key statistics

Moderna, Inc. vs Vital Farms Inc — how do they compare? Moderna, Inc. trades at $63.29 (market cap $24.18B), while Vital Farms Inc trades at $11.48 (market cap $496.50M). The key difference: Moderna, Inc. is far larger — about 48.7× Vital Farms Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals.

MRNAVITL
Market Cap
$24.18B$496.50M
Sector
HealthConsumer Staples
52-Week High
$81.80$52.41
52-Week Low
$22.36$8.28
Enterprise Value
$20.33B$583.51M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Moderna, Inc.

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.

Vital Farms Inc

VITL trades at $11.35, down 0.8% daily, with a bearish technical signal driven by moving averages. Recent Q2 2026 results showed a loss of $0.47 per share, beating expectations but reflecting revenue declines amid industry oversupply challenges. The company secured a $125 million term loan in August 2026 to bolster liquidity, as net cash flow remained negative. Valuation ratios like P/E of 11.77 and P/S of 0.67 suggest potential undervaluation, but profitability metrics are weak with net income margin at 0.02%.

The outlook is mixed: analyst consensus is bullish with a $13.00 price target, but execution risks from cost pressures and competitive gaps persist. Near-term catalysts include Q3 2026 earnings, while downside risks involve ongoing operational challenges and class-action litigation noted in May 2026. The stock's proximity to its 52-week low underscores cautious sentiment despite institutional support.

Returns comparison

Trailing returns across standard periods

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA

About Vital Farms Inc

Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.

Read more on VITL